{
  "main_header": {
    "sid": 622974,
    "name": "Panacea Biotec",
    "stock_name": "Panacea Biotec",
    "full_name": "Panacea Biotec Ltd",
    "name_url": "stocks-analysis/panacea-biotec",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "371.00",
    "chg": 4.75,
    "chgp": "1.3%",
    "dir": 1,
    "prev_price": "366.25",
    "mcapval": "2,281.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 531349,
    "symbol": "PANACEABIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE922B01023",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "98.62 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/panacea-biotec-622974-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 0,
    "sid": "622974",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/panacea-biotec-622974"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Nine Months Ended December 31 2025",
      "datetime": "02-Feb-2026",
      "details": "Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31 2025. The trading window of the Company shall remain closed for all Designated Persons (including their Immediate relatives) of the Company till February 13 2026",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "07-Jan-2026",
      "details": "We are now delighted to inform you that enrolment of study participants in context of DengiAll Phase-III clinical trial has been completed.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jan-2026",
      "details": "Please find enclosed certificate dated January 02 2026 issued by Skyline Financial Services Pvt. Ltd. Registrar and Transfer Agent of the Company confirming compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Panacea Biotec Ltd has declared <strong>75%</strong> dividend, ex-date: 19 Sep 11",
          "dt": "2011-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

No Recent News for the Company

View All News